ARTICLE | Company News
KV endocrine news
April 5, 2010 7:00 AM UTC
KV reduced headcount by 289 (42%) to 391 to save cash. KV markets EvaMist estradiol transdermal spray in the U.S. to treat moderate to severe vasomotor symptoms due to menopause. KV has rights to the...